1-5 of 5
Ole Weiss-Bjerrum
Close
Sort by
Journal Articles

Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study

Satu Mustjoki, MD, PhD, Johan Richter, MD, PhD, Gisela Barbany, MD, PhD, Hans Ehrencrona, MD, PhD, Ingunn Dybedal, MD, PhD, Thoas Fioretos, MD, PhD, Tobias Gedde-Dahl, MD, PhD, Bjorn Gjertsen, MD, PhD, Randi Hovland, PhD, Sari E Jalkanen, MSc, Dag Josefsen, MD, PhD, Perttu Koskenvesa, MD, Carin Lassen, Msc, Kirsi Latvala, Waleed Majeed, MD, Claes Malm, MD, Berit Markevärn, MD, Ali Mosfegh, PhD, Lotta Ohm, MD, Tor Olofsson, MD, PhD, Ulla Olsson-Strömberg, MD, PhD, Katrin Rapakko, PhD, Kari Remes, MD PhD, Jesper Stentoft, MD, PhD, Leif Stenke, MD, PhD, Merja Suominen, MD, Sara Thunberg, PhD, Ole Weiss Bjerrum, MD, PhD, Bengt Simonsson, MD, PhD, Kimmo Porkka, MD, PhD, Henrik Hjorth-Hansen, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 784.
https://doi.org/10.1182/blood.V118.21.784.784
Published: 2011
Journal Articles

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Clinical Trials & Observations
Bengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, Kari Remes, Jesper Stentoft, Anders Almqvist, Mats Björeman, Max Flogegård, Perttu Koskenvesa, Anders Lindblom, Claes Malm, Satu Mustjoki, Kristina Myhr-Eriksson, Lotta Ohm, Anu Räsänen, Marjatta Sinisalo, Anders Själander, Ulla Strömberg, Ole Weiss Bjerrum, Hans Ehrencrona, Franz Gruber, Veli Kairisto, Karin Olsson, Fredrik Sandin, Arnon Nagler, Johan Lanng Nielsen, Henrik Hjorth-Hansen, Kimmo Porkka, for the Nordic CML Study Group
Journal: Blood
Blood (2011) 118 (12): 3228–3235.
https://doi.org/10.1182/blood-2011-02-336685
Published: 2011
Journal Articles

The Proportion of Ph+ CD34 + CD38 neg Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study

Satu Mustjoki, MD, PhD, Johan Richter, MD, PhD, Gisela Barbany, MD, PhD, Ingunn Dybedal, MD, PhD, Thoas Fioretos, MD, PhD, Tobias Gedde-Dahl, MD, PhD, Bjorn T. Gjertsen, MD, PhD, Randi Hovland, PhD, Sari Jalkanen, Msc, Dag Josefsen, MD, PhD, Perttu Koskenvesa, MD, Carin Lassen, Kirsi Latvala, Waleed Majeed, MD, Claes Malm, MD, Berit Markevärn, MD, Ali Moshfegh, PhD, Lotta Ohm, MD, Tor Olofsson, MD, PhD, Ulla Olsson-Strömberg, MD, PhD, Katrin Rapakko, PhD, Kari Remes, MD, PhD, Jesper Stentoft, MD, PhD, Leif Stenke, MD, PhD, Merja Suominen, MD, Sara Thunberg, MD, PhD, Ole Weiss Bjerrum, MD, PhD, Bengt Simonsson, MD, PhD, Kimmo Porkka, MD, PhD, Henrik Hjorth-Hansen, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 667.
https://doi.org/10.1182/blood.V116.21.667.667
Published: 2010
Journal Articles

A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Bengt Simonsson, MD, Tobias Gedde-Dahl, MD, Berit Markevärn, MD, Kari Remes, MD, Jesper Stentoft, MD, Anders Almqvist, MD, Mats Björeman, MD, Max Flogegård, MD, Heikki Hallman, MD, Perttu Koskenvesa, MD, Anders Lindblom, MD, Claes Malm, MD, Satu Mustjoki, MD, Kristina Myhr-Eriksson, MD, Anu Räsänen, MD, Marjatta Sinisalo, MD, Risto Sippola, MD, Anders Själander, MD, Ulla Strömberg, MD, Ole Weiss Bjerrum, MD, Hans Ehrencrona, MD, Franz Gruber, MD, Veli Kairisto, MD, Karin RN Olsson, Arnon Nagler, MD, Johan Lanng Nielsen, MD, Henrik Hjorth-Hansen, MD, Kimmo Porkka, MD, for the Nordic CML Study Group (NCMLSG)
Journal: Blood
Blood (2009) 114 (22): 3280.
https://doi.org/10.1182/blood.V114.22.3280.3280
Published: 2009
Journal Articles

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Clinical Trials & Observations
Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti, Ibrahim Haznedaroglu, Kimmo Porkka, Elisabetta Abruzzese, Giuliana Alimena, Hans Ehrencrona, Henrik Hjorth-Hansen, Veli Kairisto, Luciano Levato, Giovanni Martinelli, Arnon Nagler, Johan Lanng Nielsen, Ugur Ozbek, Francesca Palandri, Fausto Palmieri, Fabrizio Pane, Giovanna Rege-Cambrin, Domenico Russo, Giorgina Specchia, Nicoletta Testoni, Ole Weiss-Bjerrum, Giuseppe Saglio, Bengt Simonsson
Journal: Blood
Blood (2009) 113 (19): 4497–4504.
https://doi.org/10.1182/blood-2008-12-191254
Published: 2009
Includes: Supplemental data